CAS: 3099-52-3; 2-(Diethylamino)Ethyl Nicotinate

上下游产品

CAS号93-60-7 烟酸甲酯 | CAS号100-37-8 二乙氨基乙醇 | CAS号20260-53-1 盐酸烟酰氯 | CAS号10400-19-8 烟酰氯 | CAS号59-67-6 烟酸 | CAS号56-23-5 四氯化碳

📜烟酸置于氯化亚砜,苯体系中,化学反应生成烟胺乙酯
参考文献:Mndshojan,Zhurnal Obshchei Khimii,1946,Vol. 16,P. 1033,1035
标题:Mndshojan,Zhurnal Obshchei Khimii,1946,Vol. 16,P. 1033,1035

专利信息

专利号:US-12221646-B2
优先权日:2013-07-04
标 题:Method for the rapid determination of susceptibility or resistance of bacteria to antibiotics
发明人：FERNÃ?NDEZ GARCÃ?A JOSÉ LUIS; GOSÃ?LVEZ BERENGUER JAIME; SANTISO BRANDARIZ REBECA; TAMAYO NOVAS MARIA; BOU ARÉVALO GERMÃ?N
权利人:ABM TECH LLC
摘要:A method of rapidly evaluating the susceptibility of a strain of bacteria to a cell wall synthesis inhibiting antibiotic based on an assessment of cell enlargement in response to doses of the cell wall synthesis inhibiting antibiotic which are correlated to breakpoints of bacterial susceptibility.

专利号:US-2023398101-A1
优先权日:2022-06-09
标题 :Co-agents as Therapy Against Anaerobic Pathogens
发明人：PACE JOHN LEE; HARTSELL THERESA LYNN
权利人:FLEURIR ABX LLC
摘要:Co-agent combinations and/or formulations herein unexpectedly display significantly better antimicrobial activity (e.g., more efficacy and/or more potency) against anaerobic pathogens not previously considered targets. With three or more co-agents, selected from a group of a fosfomycin, a diaminopyridine, a sulfonamide, a beta lactam antibacterial, a bacterial beta-lactamase inhibitor, a bacterial fosfomycin-modifying enzyme, and a bacterial peptidoglycan synthesis inhibitor, the therapeutic potential of the three or more co-agents is expanded by targeting a broader spectrum of pathogens. Co-agents, by unexpected synergistic action in an anaerobic environment, are now active and efficacious against difficult to treat pathogenic anaerobes (including anaerobes that cannot utilize oxygen and/or reside in an anaerobic environment, some being inhibited by oxygen), as well as pathogens considered resistant or intolerant to at least one of the co-agents when used singly in an anaerobic environment. Some co-agent combinations and/or formulations contain one or more existing antibiotic agents being repurposed for utility against difficult to treat anaerobic pathogens.